BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP decreased its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 50.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,024 shares of the biotechnology company’s stock after selling 51,469 shares during the quarter. Seven Fleet Capital Management LP’s holdings in BioCryst Pharmaceuticals were worth $510,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. denkapparat Operations GmbH purchased a new position in BioCryst Pharmaceuticals in the 2nd quarter valued at approximately $201,000. AXQ Capital LP boosted its position in BioCryst Pharmaceuticals by 40.0% during the second quarter. AXQ Capital LP now owns 54,534 shares of the biotechnology company’s stock worth $545,000 after purchasing an additional 15,582 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in BioCryst Pharmaceuticals during the second quarter worth $912,000. Moore Capital Management LP acquired a new stake in BioCryst Pharmaceuticals in the second quarter valued at $8,483,000. Finally, Northwestern Mutual Wealth Management Co. grew its holdings in BioCryst Pharmaceuticals by 40.2% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 10,254 shares of the biotechnology company’s stock valued at $103,000 after purchasing an additional 2,942 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on BCRX shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Thursday, August 27th. Cantor Fitzgerald lifted their target price on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 30th. Wall Street Zen downgraded shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 29th. Royal Bank Of Canada lowered their price target on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Finally, HC Wainwright restated a “buy” rating and set a $32.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th. Eight research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $20.60.

BioCryst Pharmaceuticals Stock Performance

BCRX opened at $9.96 on Friday. The company’s 50 day simple moving average is $9.75 and its 200 day simple moving average is $9.17. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.00 and a 1 year high of $11.22. The stock has a market capitalization of $2.55 billion, a PE ratio of -6.64 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. The firm had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. BioCryst Pharmaceuticals’s revenue was up 33.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.15 earnings per share. As a group, sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.